Navigation Links
Anthrax inhibitors identified by Burnham team

lone.

"This represents a significant advance in developing a possible emergency treatment for anthrax," said Dr. Pellecchia. "We are working on refining the chemical structure of the compound with the goal of achieving an even more potent and selective drug that should exhibit a higher degree of protection against anthrax."

This research was supported by grants from the National Institute of Allergy and Infectious Diseases, from the National Institutes of Health.

Coauthors on this study include:

Martino Forino, Sherida Johnson, Tian Y. Wong, Dimitri V. Rozanov, Alexei Y. Savinov, Wei Li, Roberto Fattorusso, Barbara Becattini, and Dawoon Jung, from The Burnham Institute.
Robert Liddington, Ph.D., Acting Director, Center for Infectious and Inflammatory Diseases at The Burnham Institute;
Alex Strongin, Ph.D., Professor, Cell Adhesion/Extracellular Matrix Program, The Burnham Institute;
Jeffrey Smith, Ph.D., Professor, and Director of the Center for Proteolytic Pathways at The Burnham Institute;
Ruben A. Abagyan, Ph.D., Professor, and Andrew J. Orry, Molecular Biology Department at The Scripps Research Institute;
Ken Alibek, Ph.D., National Center for Biodefense, George Mason University, Fairfax, Virginia.

###

The Burnham Institute, founded in 1976, is an independent not-for-profit biomedical research institution dedicated to advancing the frontiers of scientific knowledge and providing the foundation for tomorrow's medical therapies. The Institute is home to three major centers: the original Cancer Center, the Del E. Webb Neuroscience and Aging Center established in 1999, and the Infectious and Inflammatory Disease Center dedicated in 2004. Since 1981, the Institute's Cancer Center has earned the prestigious designation as a Non-comprehensive Cancer Center by the National Cancer Institute. Discoveries by Burnham scientists have contributed to the development of new drugs for Alzheimer's disea
'"/>

Source:Burnham Institute


Page: 1 2 3

Related biology news :

1. Study Models Impact Of Anthrax Vaccine
2. Anthrax test, developed by army and CDC, receives FDA approval
3. Anthrax stops body from fighting back, study shows
4. Anthrax spores may survive water treatment
5. Anthrax inhibitor counteracts toxin, may lead to new therapeutics
6. Anthrax attack posed greater potential threat than thought
7. Anthrax paralyzes immune cells with lethal toxin, UF research shows
8. Protease inhibitors reach beyond HIV
9. Enzyme inhibitors block replication of SARS virus
10. Sweet water taste paradoxically predicts sweet taste inhibitors
11. COX-2 inhibitors significantly reduce risk of cancer
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Anthrax inhibitors identified Burnham team

(Date:6/29/2015)... Research and Markets( http://www.researchandmarkets.com/research/zj7h4f/latin_america ) has ... Sensors Market - Growth, Trends & Forecasts (2014-2020)" ... Biomedical Sensors market is estimated at $0.65 billion by ... 2014-2020 The near future will bring Biomedical ... each individual. These sensors can be set to trigger ...
(Date:6/24/2015)... YORK , June 24, 2015 The ... rate. The major drivers for the market include growth ... number of new drug launches. Over the years, the ... increased. Between 2001 and 2010, the FDA approved 225 ... according to WIPO, Europe accounted ...
(Date:6/23/2015)...   MedNet Solutions , an innovative SaaS-based ... of clinical research, is pleased to announce that ... company,s intuitive, flexible and affordable cloud-based eClinical technology ... Award by the American Business Awards (SM) ... The American Business Awards are considered the nation,s ...
Breaking Biology News(10 mins):Latin America Biomedical Sensors Market Report 2015-2020 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4MedNet Solutions' iMedNet eClinical Wins Silver Stevie Award 2
... In a study to be published online this week in ... researchers report the discovery of a novel hepatitis C-like virus ... gives scientists new insights into how hepatitis C in humans ... a model system to study how it causes disease. ...
... Drug Administration requires every drug they certify to be ... current gold standard for this is the limulus amoebocyte ... horseshoe crabs, which strangely enough is blue, to test ... caused by bacterial infections. But researchers at the ...
... popular conception that behaviours such as repetitive hand-washing, characteristic ... to disturbing obsessive fears. The study, conducted ... University of Amsterdam, found that in the case of ... precursors to the disorder, and that obsessions may simply ...
Cached Biology News:Discovery of canine hepatitis C virus opens up new doors for research on deadly human pathogen 2Discovery of canine hepatitis C virus opens up new doors for research on deadly human pathogen 3Replacing the blue bloods 2New research provides insight into how OCD develops 2
(Date:7/2/2015)... ... 2015 , ... In’Tech Medical SAS ( http://www.intech-medical.com ), a ... the acquisition of Turner Medical, Inc ., thus becoming a global leader ... Spine Industry. The acquisition of Turner Medical ideally supplements In’Tech Medical’s product offering, ...
(Date:7/1/2015)... ... ... The next-generation sequencing (NGS) clinical market is poised for huge growth as it prepares ... in its new report that the market drivers of this vibrant industry include increased ... diagnostics as part of a molecular diagnostics trend. , The global market is forecast ...
(Date:7/1/2015)... 1, 2015 Isagenix International, a leading global ... Gold, three Silver, and three Bronze Stevie® Awards at ... Chicago this month.The American ... awards program in the U.S. "Winning ... in developing leaders, cultivating talent, creating a unified team, ...
(Date:7/1/2015)... ... July 01, 2015 , ... NEMA 4 (IP66) Medical Joysticks ... Medical Joysticks have an impermeable molecular barrier protection against bio-hazardous agents. Original ... will increase healthcare worker safety and reduce financial costs. , CTI Electronics announces ...
Breaking Biology Technology:In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 2In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 3NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 2NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 3Isagenix Earns Nine American Business Awards 2Isagenix Earns Nine American Business Awards 3Sanitized Medical Joysticks for a Safer and Healthier Work Environment 2
... be Called Kowa Pharmaceuticals America, NAGOYA, ... Kowa,Company, Ltd., a privately-held company headquartered in ... Pharmaceuticals, Inc., a,privately-held specialty pharmaceutical company based ... ProEthic will change name to Kowa,Pharmaceuticals America ...
... NanoLogix, Inc. (OTC:,NNLX) a biotechnology company, is ... and CL Solutions http://www.cl-solutions.com have signed ... Detection Bioremediation,Kits (FDBK) for use in monitoring the ... Efrain Torres, CEO of CL Solutions,stated: "We are ...
... Best and Final Offer, INDIANAPOLIS, Aug. 4 ... that its $3.00 per share purchase offer for,SGX Pharmaceutical, ... final offer,for the San Diego-based biotechnology company. On July ... definitive merger agreement, whereby,Lilly will acquire all of the ...
Cached Biology Technology:Kowa Company, Ltd. Acquires ProEthic Pharmaceuticals, Inc. 2NanoLogix Inc. Announces Joint Development With CL Solutions and First Sales of Rapid Detection Kits 2NanoLogix Inc. Announces Joint Development With CL Solutions and First Sales of Rapid Detection Kits 3Lilly Reaffirms Purchase Offer for SGX Pharmaceuticals 2Lilly Reaffirms Purchase Offer for SGX Pharmaceuticals 3
...
Dopamine D2 and D3 receptor, human and possibly mouse. AB1502 detects 40 ng of dopamine receptor peptide by ELISA. AB1502 is not neutralizing....
Rabbit polyclonal to SpUlp2 ( Abpromise for all tested applications). Antigen: Synthetic peptide: SNNERQSLSSGSND, corresponding to amino acids 622-635 of Schizosaccharomyces pombe SpUlp2...
STX18 Immunogen: STX18 (NP_058626, 101 a.a. ~ 200 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Biology Products: